We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Sciele Pharma (MM) | NASDAQ:SCRX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 31.01 | 0 | 01:00:00 |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
(Rule 14d-101)
Solicitation/Recommendation Statement Under
Section 14(d)(4) of the Securities Exchange Act of 1934
SCIELE PHARMA, INC.
(Name of Subject Company)
SCIELE PHARMA, INC.
(Name of Person(s) Filing Statement)
Common Stock, $0.001 par value per share
(Title or Class of Securities)
808627103
(CUSIP Number of Class of Securities)
Patrick P.
Fourteau
Chief Executive Officer
Sciele Pharma, Inc.
5 Concourse Parkway, Suite 1800
Atlanta, Georgia 30328
(770) 442 9707
(Name, address and telephone number of person authorized
to receive notices and communications on behalf of the person(s) filing statement)
With Copies to:
W. Tinley
Anderson, III, Esq.
Paul, Hastings, Janofsky & Walker LLP
600 Peachtree St., N. E., Suite 2400
Atlanta, GA 30308
(404) 815-2400
x Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
This Schedule 14D-9 contains the following exhibits:
Exhibit A Exhibit A is a joint press release, dated September 1, 2008, relating to the proposed acquisition of Sciele Pharma, Inc. by Shionogi & Co., Ltd.
Exhibit B Exhibit B is a script of a presentation to analysts made on September 2, 2008.
1
1 Year Sciele Pharma (MM) Chart |
1 Month Sciele Pharma (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions